Raleigh, NC (PRWEB) September 21, 2011
The National Institutes of Health (NIH) has awarded Agile Sciences a $545,000 Phase I SBIR “SHIFT” Grant to support development of the Company’s proprietary Agilyte™ compounds to treat drug-resistant bacterial infections. Bacterial infections are responsible for an estimated 100,000 deaths in the United States each year, and despite the dire unmet medical need, few new treatment options are being developed. Agile Sciences is evaluating a new therapeutic approach to combat drug-resistant infections using molecules discovered by co-founders Dr. Christian Melander and Dr. John Cavanagh at North Carolina State University.
Agile Sciences’ Chief Executive Officer, Mr. Keith Stoneback, stated, “This award provides key support and validation of the Agile Sciences’ pharmaceutical value proposition, which is a top priority for our company. As a rapidly growing Small Business, we are especially enthusiastic about the job creation that is facilitated by this award.”
Agile Sciences’ co-founder, Dr. John Cavanagh, commented, “We are excited to transition our academic discoveries into a translational research program at Agile Sciences with the goal of providing a new therapeutic that may ultimately treat infections that are resistant to current antibiotic therapies.”
About Agile Sciences:
Agile Sciences is headquartered on North Carolina State University's Centennial Campus. The company was founded in 2007 by Professors Christian Melander and John Cavanagh of North Carolina State University (NCSU) to provide commercial solutions to those industries plagued by the effects of biofilms. The company's proprietary compounds are derived from the Agelas conifera sea sponge and have been shown to be effective in dispersing biofilms. For additional information, please visit: http://www.agilesci.com